Trial Profile
Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase III, Multicenter Trial With Post-study Follow-up
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Ropeginterferon alfa-2b (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ENDURE-CML-IX
- 30 Mar 2023 Status changed from active, no longer recruiting to completed.
- 14 Mar 2023 This trial has been completed in France (End Date: 12 Dec 2022) according to European Clinical Trials Database record.
- 13 Dec 2022 Results reporting safety and efficacy data from german CML-Study group presented at the 64th American Society of Hematology Annual Meeting and Exposition